Lung Cancer / Mesothelioma
In my earliest introductory post about SCLC, I described the typical staging breakdown used clinically, which is essentially divided into limited disease SCLC (LD-SCLC), which is typically treated with chemo and chest radiation together, with curative intent, and extensive disease SCLC (ED-SCLC), which is typically treated with chemo alone and is not considered conventionally curable. But […]
0 CommentsHere’s a situation in which I learned something from the questions raised by people here online. A handful of people with extensive disease small cell lung cancer (ED-SCLC) in the last year or two have mentioned receiving radiation for areas of residual apparent disease after receiving initial chemotherapy. I had noted that I had never […]
0 CommentsOne topic that is rarely considered in the management of SCLC is the role of surgery. The main reason is that the vast majority of patients presenting with SCLC either have extensive disease that has spread throughout the body (2/3 of SCLC presentations) or at least already have rather bulky nodal disease that would […]
4 Comments Last year, I had the occasion in two prior posts (here and here) to highlight a new agent called amrubicin that is being studied in relapsed SCLC. At an ASCO conference where most of the news in SCLC was disappointing, amrubin studies again appeared promising.
The first of these studies was reported by Dr. David Ettinger at […]
As described in my last post, one of the interesting points we’ve seen from the recent trial of maintenance alimta vs. placebo after first line chemo for advanced NSCLC is that alimta’s beneficial effects appear to be concentrated on the 2/3 of patients with non-squamous cancers, while the patients with squamous cell NSCLC did […]
0 CommentsGetting back to the issue of differences in side effects and efficacy of treatments based on differences in individuals and populations, let’s continue the story of how different populations appear to have significant differences in how the do on the same treatment regimen. In a recent prior post I described the SWOG-Japanese research collaboration […]
0 CommentsWhile the differences in anticipated clinical benefits from EGFR tyrosine kinase inhibitors like tarceva and iressa are well known (summarized in prior post), less well appreciated is the potentially significant differences in results with garden variety standard chemotherapy. These differences are likely to be very relevant as the US has a harder time getting […]
0 CommentsMember Wendy asked me about a drug called picoplatin that I had heard of but really didn’t have much familiarity with. This gave me an occasion to flesh out some background on this agent, which is being developed as a potential therapy for patients previously treated for lung cancer. Developed by Poniard Pharmaceuticals in South […]
3 CommentsThere’s been several discussions about the potential value of maintenance therapy after the initial chemotherapy for SCLC; I’ve discussed this subject in a prior post, in which I focused on chemo (prior post here) — while the results haven’t been strong enough to lead to a change in standard practice, at least one trial […]
0 Comments Dr. Laskin has appreciated the warm welcome. Not only have you not scared her off, she’s written her first post for us.
By the way, it’s misleading to have my name and picture and “about the author” next to these posts by our new faculty — the software upgrade will fix this. Here’s her […]
Posts
| Core Concepts
| Subject Archives
| Monthly Archives
| Resources
| 
Donate
| Forums
| GRACE Home
Disclaimer: The information provided at GRACE is for informational purposes only. The faculty of GRACE is not providing medical advice, diagnosis or treatment and cannot replace the medical advice of your doctor or health care provider. (Full Disclaimer)
© 2007-2008 GRACE. All rights reserved.
